PT - JOURNAL ARTICLE AU - , TI - Burden of PCR-Confirmed SARS-CoV-2 Reinfection in the U.S. Veterans Administration, March 2020 – January 2022 AID - 10.1101/2022.03.20.22272571 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.20.22272571 4099 - http://medrxiv.org/content/early/2022/03/23/2022.03.20.22272571.short 4100 - http://medrxiv.org/content/early/2022/03/23/2022.03.20.22272571.full AB - An essential precondition for successful “herd immunity” strategies for the control of SARS-CoV-2 is that reinfection with the virus be relatively rare. Some infection control, prioritization, and testing strategies for SARS-CoV-2 were designed on the premise of rare re-infection. The U.S. Veterans Health Administration (VHA) includes 171 medical centers and 1,112 outpatient sites of care, with widespread SARS-CoV-2 test availability. We used the VHA’s unified, longitudinal electronic health record to measure the frequency of re-infection with SARS-CoV-2 at least 90 days after initial diagnosisWe identified 308,051 initial cases of SARS-CoV-2 infection diagnosed in VHA between March 2020 and January 2022; 58,456 (19.0%) were associated with VHA hospitalizations. A second PCR-positive test occurred in 9,203 patients in VA at least 90-days after their first positive test in VHA; 1,562 (17.0%) were associated with VHA hospitalizations. An additional 189 cases were identified as PCR-positive a third time at least 90-days after their second PCR-positive infection in VHA; 49 (25.9%) were associated with VHA hospitalizations.The absolute number of re-infections increased from less than 500 per month through November 2021, to over 4,000 per month in January 2022.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by VA HSR&D C19-21-278 and C19-21-279.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:These analyses were given ethical approval for this work under expedited review by the institutional review boards of the Veterans Affairs Medical Centers of Puget Sound, Portland, Ann Arbor, and Durham.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in partnership with VA investigators via VA data approval processes.